Conic, I.; Nedovic, B.; Stojnev, S.; Todorovska, I.; Dimitrijevic, A.; Krstic, M.; Djordjevic, I.; Djordjevic, B.
Bevacizumab with Chemotherapy as a First-Line Treatment for Advanced Ovarian Cancer in a Serbian Cohort. Medicina 2022, 58, 607.
https://doi.org/10.3390/medicina58050607
AMA Style
Conic I, Nedovic B, Stojnev S, Todorovska I, Dimitrijevic A, Krstic M, Djordjevic I, Djordjevic B.
Bevacizumab with Chemotherapy as a First-Line Treatment for Advanced Ovarian Cancer in a Serbian Cohort. Medicina. 2022; 58(5):607.
https://doi.org/10.3390/medicina58050607
Chicago/Turabian Style
Conic, Irena, Bojan Nedovic, Slavica Stojnev, Ilinka Todorovska, Aleksandra Dimitrijevic, Miljan Krstic, Ivana Djordjevic, and Biljana Djordjevic.
2022. "Bevacizumab with Chemotherapy as a First-Line Treatment for Advanced Ovarian Cancer in a Serbian Cohort" Medicina 58, no. 5: 607.
https://doi.org/10.3390/medicina58050607
APA Style
Conic, I., Nedovic, B., Stojnev, S., Todorovska, I., Dimitrijevic, A., Krstic, M., Djordjevic, I., & Djordjevic, B.
(2022). Bevacizumab with Chemotherapy as a First-Line Treatment for Advanced Ovarian Cancer in a Serbian Cohort. Medicina, 58(5), 607.
https://doi.org/10.3390/medicina58050607
